Clinical Trial Update: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for CRD in carfilzomib-refractory multiple myeloma (Phase 1/2). Results have been posted as of 2024-04-05.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CRD

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-04-05